MMSI · Merit Medical Systems Inc
Market Cap
$5.35B
Shares
59.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$90.49
Open$89.96
Day$89.28–90.72
52W close$60.31–93.18
Avg vol 30d990K
Short int3.5M · 5.8% float · 2.8d
Short vol44%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 30, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 14.4 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
+14%
above
RSI (14)
65
neutral
MACD trend
Negative
52-week position
92%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+26%
trailing
YTD return
+3%
this year
Relative strength
+12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $80 › 200d $77 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +65 funds added
Insider flow
Distributing
Net -$2.5M over 90 days · 100% sells
Short interest
Falling
5.79% of float · ▼ -7.6% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
402 holders — near 3-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
+12%
Y/Y
Gross margin
49%
expanding
EPS growth
+5%
Y/Y
Free cash flow
$215.7M
Valuation
P/E 36.9
below peers
Balance sheet
$287.6M
net debt
Quant / Vol
risk profile
Volatility
30%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
2.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Total Revenue
· Year Ending December 31, 2026
Initiated
$1.63B – $1.64B
prior FY $1.52B
midpoint +8.0% Y/Y
Non-GAAP Earnings Per Share
· Year Ending December 31, 2026
Non-GAAP
Initiated
$4.25 – $4.35
Prior guidance
period ended
· from the 8-K filed Oct 30, 2025
Net Sales
· Year Ending December 31, 2025
$1.5B – $1.52B
Cardiovascular Segment
· Year Ending December 31, 2025
$1.43B – $1.44B
Endoscopy Segment
· Year Ending December 31, 2025
$72M – $74M
Guided vs delivered
· last 3 settled
Net Sales
Year Ending December 31, 2025
guided $1.5B – $1.52B
$1.52B
Beat +0.5%
GAAP diluted earnings per share
fiscal year 2023
guided $1.71 – $1.79
$1.62
Miss −7.4%
GAAP diluted earnings per share
fiscal year 2022
guided $1.13 – $1.90
$1.29
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
65
Neutral
MACD trend
Negative
Bearish
52-week position
92%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $80 › 200d $77 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +65 funds added
Insider flow
Distributing
Net -$2.5M over 90 days · 100% sells
Short interest
Falling
5.79% of float · ▼ -7.6% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
402 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $60
Now $90 · 92%
Range high $93
vs 200-day avg +18%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Constant Currency Revenue non-GAAP | 789.8M | Six Months Ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Reported Revenue 800.72M
-10.92M Impact of foreign exchange
= Constant Currency Revenue 789.8M
|
|||
| Constant Currency Revenue, Organic non-GAAP | 774.45M | Six Months Ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Constant Currency Revenue 789.8M
-13.7M Revenue from certain acquisitions
-1.64M Revenue from divestitures (b)
= Constant Currency Revenue, Organic 774.45M
|
|||
| Free Cash Flow non-GAAP | 76.62M | Six Months Ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Reported Cash Flow from Operations 109.96M
-33.34M Capital Expenditures
= Free Cash Flow 76.62M
|
|||
| Non-GAAP EPS non-GAAP | $2.13 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Non-GAAP Gross Margin non-GAAP | 54.6% | Six Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Reported Gross Margin $50
+$4.6 Amortization of intangibles
+$0 Inventory mark-up related to acquisitions
= Non-GAAP Gross Margin $54.6
|
|||
| Non-GAAP Net Income non-GAAP | 127.94M | Six Months Ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP net income 79.8M
+28.22M Amortization of intangibles (Cost of Sales)
-29K Contingent consideration benefit
+3.78M Amortization of intangibles (Operating Expenses)
+11.37M Performance-based share-based compensation (a)
+1.65M Corporate restructuring (b)
+5.91M Acquisition-related
+1.58M Medical Device Regulation expenses (c)
+6.03M Long-term debt costs (e)
-10.98M Gain on disposal of business unit
+618K Other non-operating loss (f)
= Non-GAAP net income 127.94M
|
|||
| Non-GAAP Operating Income non-GAAP | 169.89M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Non-GAAP Operating Margin non-GAAP | 21.2% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Constant currency revenue adjustment non-GAAP | -$7.9M | Three Months Ended March 31, 2026 | — |
| Constant currency revenue growth non-GAAP | 5% | Q1 FY2026 | — |
| Constant currency revenue, organic growth non-GAAP | 3% | Q1 FY2026 | — |
|
|
|||
| Constant Currency Revenue, Organic, excluding impact of divested product line non-GAAP | $363.25M | Three Months Ended March 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Constant Currency Revenue, Organic 364.9M
-1.64M Revenue from divested product line, DualCap®
= Constant Currency Revenue, Organic, excluding impact of divested product line 363.25M
|
|||
| Capital Expenditures-Property and Equipment | $81.7M | FY 2025 | — |
| Operating Cash Flow | $297.4M | FY 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MMSI
this stock
Merit Medical Systems Inc
|
$5.35B | +2.7% | +11.8% | 36.9 | 5.8% |
|
ISRG
Intuitive Surgical Inc
|
$129.68B | -34.2% | +20.5% | 42.1 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$51.81B | — | +8.2% | — | 3.4% |
|
MDLN
Medline Inc.
|
$45.55B | -16.0% | +11.5% | — | 2.8% |
|
ALC
Alcon Inc
|
$34.81B | -8.6% | +10.5% | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MMSI | -0.3% | +6.5% | +25.9% | +6.5% | +2.7% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -0.8% | +3.5% | +12.5% | +3.5% | -10.2% |
Capital returns
Buyback program
· as of Apr 30, 2007
Authorized
shares 1.40M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.